| Stage | EOG | % of rev | EPSN | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $8.6B | 100.00% | $18M | 100.00% | EOG ×468.85 |
| Gross profit | $7.4B | 86.65% | $18M | 97.22% | EPSN +10.6pp |
| Operating income | $3.5B | 41.21% | $8M | 45.88% | EPSN +4.7pp |
| Pre-tax income | $3.5B | 40.87% | $10M | 52.36% | EPSN +11.5pp |
| Net income | $2.7B | 31.81% | $7M | 39.06% | EPSN +7.2pp |
| Stage | EOG | EPSN | Gap · A − B |
|---|---|---|---|
| Revenue | $8.6B100.00% | $18M100.00% | EOG ×468.85 |
| Gross profit | 86.65%$7.4B | 97.22%$18M | EPSN +10.6pp |
| Operating income | 41.21%$3.5B | 45.88%$8M | EPSN +4.7pp |
| Pre-tax income | 40.87%$3.5B | 52.36%$10M | EPSN +11.5pp |
| Net income |
| 31.81%$2.7B |
| 39.06%$7M |
| EPSN +7.2pp |
No shared counterparties.